Known targets — ChEMBL curated mechanism
MTORPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Omipalisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 20/20 | 1.00 |
| ▸ | MTOR known ✓ | P42345 | 8/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 4/20 | 1.00 |
| ▸ | PIK3CB known ✓ | P42338 | 4/20 | 1.00 |
| ▸ | PIK3CG known ✓ | P48736 | 4/20 | 1.00 |
| ▸ | PIK3R1 known ✓ | P27986 | 1/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | RICTOR | Q6R327 | 1/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 1/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 1.00 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 1.00 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 1.00 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omipalisib SCHEMBL29358168 | 1.00 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| Omipalisib SCHEMBL29352875 | 1.00 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL20734873 | 0.93 | PIK3CA (0.88) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL741445 | 0.92 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16454210 | 0.91 | PIK3CA (0.83) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL23121496 | 0.90 | PIK3CA (0.82) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL17060446 | 0.90 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL25495105 | 0.89 | PIK3CA (0.84) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1300383 | 0.89 | PIK3CA (0.86) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL21964236 | 0.89 | PIK3CA (0.82) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1010 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252454-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2024-08-01 | — | — | US | claimed |
| EP-4333822-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | Lead Discovery Center GmbH (DE) | 2024-03-13 | — | — | EP | claimed |
| WO-2022233782-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-10 | — | — | WO | claimed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| US-20210186980-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | SOVARGEN CO., LTD. (KR) | 2021-06-24 | — | — | US | claimed |
| EP-3266455-B1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING MTOR INHIBITOR | KOREA ADVANCED INST SCI & TECH (KR) | 2020-12-30 | — | — | EP | claimed |
| US-20200390889-A1 | REMOTELY TRIGGERED THERAPY | BAMBU VAULT LLC (US) | 2020-12-17 | — | — | US | claimed |
| US-10351916-B2 | Method for identification of anti-HIV human miRNA mimics and miRNA inhibitors and anti-HIV pharmaceutical compounds | CSIR (ZA) | 2019-07-16 | — | — | US | claimed |
| US-10323228-B2 | Differentiation of hepatocyte-like cells from stem cells | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-06-18 | — | — | US | claimed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | claimed |
| EP-2162131-B1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-03-06 | — | — | EP | claimed |
| US-20120245180-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2012-09-27 | — | — | US | claimed |
| EP-2488184-A1 | COMBINATION | GlaxoSmithKline LLC (US) | 2012-08-22 | — | — | EP | claimed |
| US-20120202822-A1 | COMBINATION | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | claimed |
| EP-2482819-A2 | COMBINATION | GlaxoSmithKline LLC (US) | 2012-08-08 | — | — | EP | claimed |
| WO-2012068339-A2 | METHODS OF TREATING CANCER | GLAXOSMITHKLINE LLC (US) | 2012-05-24 | — | — | WO | claimed |
| US-8138347-B2 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-03-20 | — | — | US | claimed |
| WO-2012021480-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2012-02-16 | — | — | WO | claimed |
| WO-2011046894-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2011-04-21 | — | — | WO | claimed |
| WO-2011038380-A2 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2011-03-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245180-A1 | COMBINATION | PIK3CA, BRAF, PIK3CD | PIK3CA 1/4885MTOR 129/4885PIK3CD 3/4885 |
| US-20200390889-A1 | REMOTELY TRIGGERED THERAPY | CD47, IFNG, TLR9 | PIK3CA 2448/4885MTOR 4297/4885PIK3CD 3463/4885 |
| US-20120202822-A1 | COMBINATION | PIK3CA, BRAF, PIK3CD | PIK3CA 1/4885MTOR 230/4885PIK3CD 3/4885 |
| US-20240252454-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | TFAM, POLRMT, TUFM | PIK3CA 2374/4885MTOR 1689/4885PIK3CD 1778/4885 |
| US-20210186980-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | MTOR, MAPKAP1, RPTOR | PIK3CA 358/4885MTOR 1/4885PIK3CD 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.